In the public health system, A Disintegrin And Metalloprotease with ThromboSpondin type 1 motif, member 13 (ADAMTS13) activity assays and complement inhibitors (eculizumab and ravulizumab), humanized monoclonal antibodies that block complement component C5 and currently represent the standard etiologic treatment for complement-mediated TMAs, including atypical HUS, are generally not available in routine practice. Here, C5 is linked to hemolytic-uremic syndrome.